BioSig Subsidiary ViralClear Submits Application For Vicromax™ Through FDA's Coronavirus Treatment Acceleration Program (CTAP) To Seek Acceleration Of Its Planned Clinical Trials

Press/Media: Expert Comment

PeriodApr 21 2020

Media coverage

11

Media coverage

Keywords

  • COVID-19